Device Trial Radar · NCT03694210
EndoRotor DEN (Direct Endoscopic Necrosectomy)Trial
Last checked: Nov 20, 2026Latest source record: Nov 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Nov 15, 2018
Primary completion
Aug 22, 2019
Study completion Aug 22, 2019
Sponsor
- Lead sponsor
- Interscope, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 3, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, single arm, open label, multi-center, trial to evaluate the safety and effectiveness of the Interscope EndoRotor® Resection System in subjects requiring direct endoscopic necrosectomy (DEN) with walled off pancreatic necrosis (WOPN).
Conditions
- Acute Pancreatic Necrosis
- Acute Pancreatitis
- Necrotizing Pancreatitis
Interventions
EndoRotor TherapyDevice
To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Number of Participants With Device Related ComplicationsTime frame: 21 +/- 7 Days
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Benjamin Tharian
Little Rock, Arkansas
Stanford University Medical Center
Palo Alto, California
California Pacific Medical Center - Sutter Health
San Francisco, California
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.